Summary
Updated Aug 30, 2026
John R. Stuelpnagel is Director of 10x Genomics, Inc. (TXG). 3 SEC Form 4 filings on record going back to 2025, most recently on 13 August 2026. Most recent open-market trade: sold $176K of TXG on 13 August 2026. Lifetime open-market sales: $1.16M.
Recent Transactions
4Every recent SEC Form 4 transaction John R. Stuelpnagel has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies John R. Stuelpnagel files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Serge Saxonov - $4.79M of TXG open-market activity in the last 12 months
- Adam Taich - $1.84M of TXG open-market activity in the last 12 months
- Benjamin J. Hindson - $1.46M of TXG open-market activity in the last 12 months
- Sarah A. Teichmann - $579K of TXG open-market activity in the last 12 months
- Shehnaaz Suliman - $327K of TXG open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is John R. Stuelpnagel?
John R. Stuelpnagel is a corporate insider, tracked as Director of 10x Genomics, Inc. (TXG). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has John R. Stuelpnagel submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has John R. Stuelpnagel been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($1.16M) across all tracked filings.
Where can I see all of John R. Stuelpnagel's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow John R. Stuelpnagel and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
